Aktiesnakken — August 2011
-
H+H præciserer sine forventninger for regnskabsåret 2011 til et EBITDA før
særlige poster i niveauet DKK 100-110 mio. mod tidligere udmeldt i
niveauet DKK 100-140 mio. -
-

-
her handler man GXG http://gxgmarkets.com/handelsberettigede.php
-
lidt "no-news" fra exiqon:
-
Exiqon, LEO Pharma, Bispebjerg Hospital, Gentofte Hospital, Rigshospitalet og Københavns Universitet offentliggør validering af biomarkører for patienter med kroniske hudsygdomme
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind